---
title: "Ascendis says TransCon CNP achondroplasia trial shows continued leg-alignment gains at Week 104"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291283724.md"
description: "Ascendis Pharma reported two-year data from its ApproaCH trial for TransCon CNP in achondroplasia patients. Presented at ICCBH 2026, results showed continued improvement in lower-limb alignment through Week 104, with stronger benefits in patients with preexisting leg bowing. The safety profile remained consistent over two years, featuring mostly mild-to-moderate side effects and no treatment discontinuations."
datetime: "2026-06-30T12:32:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291283724.md)
  - [en](https://longbridge.com/en/news/291283724.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291283724.md)
---

# Ascendis says TransCon CNP achondroplasia trial shows continued leg-alignment gains at Week 104

-   Ascendis Pharma disclosed 2-year data from its completed pivotal ApproaCH trial; results were presented at ICCBH 2026. \* Once-weekly TransCon CNP showed continued improvement in lower-limb alignment in children with achondroplasia through Week 104. \* Benefits appeared stronger in patients who entered the study with preexisting leg bowing, a complication that can drive pain and surgery. \* Safety profile remained broadly consistent over two years, with mostly mild-to-moderate side effects and no treatment discontinuations reported. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300830PRIMZONEFULLFEED9754718) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)

## Related News & Research

- [Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong](https://longbridge.com/en/news/292392728.md)
- [Ascendis Pharma reports Week 104 ApproaCH trial data showing improved leg alignment with TransCon CNP in achondroplasia](https://longbridge.com/en/news/290873855.md)
- [Clarity Pharmaceuticals reports two additional complete responses in SECuRE trial 8 GBq 67Cu-SAR-bisPSMA cohort](https://longbridge.com/en/news/294972498.md)
- [09:30 ETNot All Recovery Boots Are Built the Same: What Shoppers Should Compare Before Buying](https://longbridge.com/en/news/294520687.md)
- [Marks Group Wealth Management Inc Purchases New Shares in Ascendis Pharma A/S $ASND](https://longbridge.com/en/news/293016157.md)